Terlipressin-induced hyponatremic encephalopathy in a noncirrhotic patient
Terlipressin, an analogue of vasopressin, is frequently used for the management of esophageal varices bleeding and hepatorenal syndrome. Terlipressin therapy in portal hypertensive patients is frequently associated with hyponatremia, but is rarely ...
Yao-Kuang Wang +5 more
doaj +3 more sources
Terlipressin Induced Severe Hyponatremia
Terlipressin is a vasopressin analogue used for its vasoconstrictor effect in the treatment of variceal bleeding. Despite its good safety profile compared to vasopressin, some adverse reactions may occur during its use – e.g. hyponatremia.
Martin Šíma +3 more
doaj +2 more sources
Purpose Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.Materials and Methods This pilot ...
Jinlong Wang +9 more
doaj +2 more sources
Vasopressin and Terlipressin in the Treatment of Vasodilatory Septic Shock: A Systematic Review
Background: Vasodilatory septic shock unresponsive to fluid resuscitation requires the addition of vasopressors. Catecholamines remain the first line vasopressor therapy, but treatment failure is a potential problem.
Jie Lin Soong BSc (Pharm) (Hons) +1 more
doaj +2 more sources
Terlipressin‐induced skin necrosis in cirrhotic patients—A case report and comprehensive literature review [PDF]
Key Clinical Message The occurrence of terlipressin‐induced skin necrosis in cirrhotic patients is a rare but serious adverse event that warrants further investigation.
Ashraf I. Ahmed +6 more
doaj +2 more sources
Severe Bradycardia Associated with the Use of Terlipressin: A Case Report
Introduction: Although terlipressin is known to cause bradycardia, this adverse effect is usually described in association with hypertension and is considered a benign compensatory response mediated by arterial baroreceptors.
Alex Yartsev, Jessica T. Nguyen
doaj +2 more sources
Prolonged Terlipressin Therapy as a Bridge to Curative TIPS for HRS-AKI in a Nontransplant Candidate. [PDF]
Hepatorenal syndrome–acute kidney injury (HRS–AKI) is a severe complication of advanced cirrhosis with high mortality and limited treatment options. Terlipressin is currently the only FDA‐approved therapy for HRS, though recurrence is common upon discontinuation in patients without access to liver transplantation.
Reidy D +3 more
europepmc +2 more sources
Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure. [PDF]
ABSTRACT Background & Aims Hepatorenal syndrome‐acute kidney injury (HRS‐AKI) is a life‐threatening complication of decompensated cirrhosis. The US Food and Drug Administration approved terlipressin use for HRS‐AKI based on the CONFIRM study, which demonstrated a significant improvement in HRS reversal with terlipressin versus placebo.
Rockey DC +7 more
europepmc +2 more sources
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome-Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical Studies. [PDF]
In a pooled analysis, bradycardia was observed in 6% of terlipressin‐treated patients but rarely required a dose interruption or reduction. Arrhythmia serious adverse event incidences were low and similar in both treatment groups. Routine intensive cardiac monitoring for the detection of arrhythmias may not be necessary during terlipressin ...
Bajaj JS +6 more
europepmc +2 more sources
Effectiveness of terlipressin for prevention of complications after major liver resection - A randomized placebo-controlled trial. [PDF]
BACKGROUND Elevated portal pressure in response to major liver resection is associated with impaired liver regeneration and increased postoperative complications.
Perrodin, Stéphanie +4 more
core +1 more source

